Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 7/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.68 |
| ▸ | KDR | P35968 | 9/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.62 |
| ▸ | HIPK4 | Q8NE63 | 4/20 | 0.62 |
| ▸ | PLK4 | O00444 | 2/20 | 0.62 |
| ▸ | AURKA | O14965 | 2/20 | 0.62 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 2/20 | 0.62 |
| ▸ | LCK | P06239 | 2/20 | 0.62 |
| ▸ | FYN | P06241 | 2/20 | 0.62 |
| ▸ | LYN | P07948 | 2/20 | 0.62 |
| ▸ | RET | P07949 | 2/20 | 0.62 |
| ▸ | SRC | P12931 | 2/20 | 0.62 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.62 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.62 |
| ▸ | AXL | P30530 | 2/20 | 0.62 |
| ▸ | FRK | P42685 | 2/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27880957 | 0.91 | RAF1 (0.58) | RAF1EPHX2KDRMAPK14HIPK4 | |
| SCHEMBL257980 | 0.90 | RAF1 (0.82) | RAF1EPHX2KDRMAPK14HIPK4 | |
| SCHEMBL13004737 | 0.88 | RAF1 (0.69) | RAF1EPHX2KDRMAPK14HIPK4 | |
| SCHEMBL3653979 | 0.88 | RAF1 (0.69) | RAF1EPHX2KDRMAPK14HIPK4 | |
| SCHEMBL13648120 | 0.87 | RAF1 (0.64) | RAF1EPHX2KDRMAPK14HIPK4 | |
| SCHEMBL5319531 | 0.87 | KDR (0.67) | RAF1EPHX2KDRMAPK14HIPK4 | |
| SCHEMBL1532339 | 0.86 | RAF1 (0.77) | RAF1EPHX2KDRMAPK14HIPK4 | |
| SCHEMBL10163311 | 0.85 | RAF1 (0.76) | RAF1EPHX2KDRMAPK14HIPK4 | |
| SCHEMBL13004684 | 0.85 | RAF1 (0.65) | RAF1EPHX2KDRMAPK14HIPK4 | |
| SCHEMBL12391532 | 0.85 | RAF1 (0.76) | RAF1EPHX2KDRMAPK14HIPK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119667011-A | Method for measuring compound | 四川科伦药物研究院有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-20230212679-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-07-06 | — | — | US | disclosed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| US-8445687-B2 | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process | CIPLA LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-8445687-B2 | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process | CIPLA LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-8445687-B2 | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process | CIPLA LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-8445687-B2 | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process | CIPLA LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| WO-2009034308-A3 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LTD (IN) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009034308-A2 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LIMITED (IN) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009034308-A2 | PROCESS FOR THE PREPARATION OF A RAF KINASE INHIBITOR AND INTERMEDIATES FOR USE IN THE PROCESS | CIPLA LIMITED (IN) | 2009-03-19 | — | — | WO | disclosed |
| EP-1968589-A2 | COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER | Bayer Pharmaceuticals Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1824843-A2 | INHIBITORS OF PROTEIN KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007053574-A2 | COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2006062984-A2 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212679-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | VEGFA, BRAF, FLT4 | RAF1 9/4885EPHX2 1724/4885KDR 4/4885 |
| US-20100311980-A1 | Process for the Preparation of a RAF Kinase Inhibitor and Intermediates for Use in the Process | BRAF, RAF1, ARAF | RAF1 2/4885EPHX2 483/4885KDR 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.